After 4 months of trying to work out an arrangment with Lilly, Amylin took the step to file a lawsuit in Federal court accusing Lilly of antic-competitive behavior in striking a deal with rival Boehringer Ingellheim to sell that company's new diabetes medication, linagliptin (or Tradjenta).
Amylin says this is in direct conflict with its agreement with Lilly to sell Byetta and its soon to be licensed (it hopes) next gen version called Bydureon. Both are based on exenatide and are targeted at the same type 2 diabetes patients as linagliptin. Amylin says in its suit that it is seeking to block Lilly from using the same sales force to sell both company's products.
An Amylin statement said the company was disapponted that "we could not resolve this matter amicably" and thus took the legal route for relief. Amylin says it still wants to work with Lilly on additional exenatide based products.
At least one analyst commented, that Amylin might be inclined to pick a new partner (or even be acquired) if the right match came along and it could teminate the Lilly agreement at reasonable cost and have its selling efforts covered. Meanwhile, Bydureon activities are still pending and the court case goes on. See Fierce Biotech and Pharmalot blog.
Posted by Bruce Lehr May 16th 2011.